Generic Hemady Availability
Last updated on Apr 10, 2025.
Hemady is a brand name of dexamethasone, approved by the FDA in the following formulation(s):
HEMADY (dexamethasone - tablet;oral)
-
Manufacturer: DEXCEL
Approval date: October 3, 2019
Strength(s): 20MG [RLD]
Is there a generic version of Hemady available?
No. There is currently no therapeutically equivalent version of Hemady available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Hemady. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions comprising dexamethasone
Patent 10,537,585
Issued: January 21, 2020
Inventor(s): Kreyenborg Caterina & Meimberg Elisabeth & Tissen Corinna & Bannefeld Karl-Heinz & Gold Tomer
Assignee(s): DEXCEL PHARMA TECHNOLOGIES LTD.A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
Patent expiration dates:
- December 18, 2037✓
- December 18, 2037
-
Compositions comprising dexamethasone
Patent 11,304,961
Issued: April 19, 2022
Inventor(s): Kreyenborg; Caterina et al.
Assignee(s): DEXCEL PHARMA TECHNOLOGIES LTD. (Or-Akiva, IL)A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
Patent expiration dates:
- December 18, 2037✓✓
- December 18, 2037
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- October 3, 2026 - INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
More about Hemady (dexamethasone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (9)
- Side effects
- Dosage information
- During pregnancy
- Drug class: glucocorticoids
- Breastfeeding
- En español
Patient resources
Other brands
Decadron, Dexamethasone Intensol, TaperDex, ZoDex, ... +4 more
Professional resources
Other brands
Decadron, TaperDex, ZoDex, Dexpak Taperpak, ... +6 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
